Author

Ralph R. Weichselbaum

University of ChicagoORCID 0000-0002-5643-8939Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

Ainhoa ArinaiD· 1 shared Aleksandra Zieminska· 1 shared Annika M. Sääf· 1 shared Anthony A. KossiakoffiD· 1 shared Edwin J. Arauz· 1 shared Elham MasoumiiD· 1 shared Jaehyun LeeiD· 1 shared Joshua GlazieriD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

Ainhoa ArinaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Synthetic BiologybioRxivPreprintAug 17, 2026

Programmable genetic control of tumor-colonizing Bifidobacterium longum for intratumoral therapeutic delivery and biocontainment

Jaehyun Lee, Joshua Glazier, Ralph R. Weichselbaum, Mark Mimee

This paper develops a genetic control system for Bifidobacterium longum to regulate its activity in tumors, enabling therapeutic delivery and biocontainment.

DOI 10.64898/2026.08.12.744520

humanproteomics

𝕏 PostBluesky

BioengineeringScience AdvancesPeer-reviewedJul 4, 2025

A new universal chimeric-antigen receptor (CAR)- fragment antibody binder (FAB) split system for cancer immunotherapy

Ainhoa Arina, Edwin J. Arauz, Karolina Warzecha…·Anthony A. Kossiakoff

This paper introduces a modular CAR-Fab platform that improves cancer immunotherapy by enabling rapid target redirection and reducing antigen loss variant escape.

5 citations

humanproteomics

𝕏 PostBluesky